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     INTRODUCTION 
  Praziquantel (PZQ) is the only current drug of choice for 
the treatment of schistosomiasis, with the 54th World Health 
Assembly setting a target of treating 75% of school-age 
children in high endemic regions by the end of 2010.  1   The 
Ugandan National Government, with assistance from the 
Schistosomiasis Control Initiative (SCI), has administered 
mass PZQ treatment over 7 years, with infection prevalences 
greatly reduced from 33.4–49.3% to 9.7–29.6% and intensi-
ties reduced from 105.7–386.8 eggs per gram (epg) of feces to 
11.6–84.1 epg in the first 2 years alone.  2,  3   Analyses of qualita-
tive data from the control program within Uganda are also 
reporting an increased demand for continued treatment, likely 
to lead to further widespread PZQ use.  4   There are, as of yet, no 
clear reports of PZQ resistance, including in China with over 
20 years of treatment; there were early concerns of resistance 
in Egypt,  5   but resistance was not observed to have spread with 
continued mass drug administration (MDA).  6   However, the 
relatively new strong MDA selective pressures now occurring 
in sub-Saharan Africa are acting without the high refugia found 
in   Schistosoma japonicum   populations or the additional con-
straining pressures of intense mollusciding as has been imple-
mented for over 50 years in both Egypt and China,  7,  8   both of 
which could dilute and/or limit any potential adaptation and 
establishment of PZQ-resistant genotypes. Crucially, MDA on 
  Schistosoma mansoni   populations in sub-Saharan Africa has 
very recently been shown to impact the parasite population 
diversity,  9   which could indicate early changes, such as poten-
tial development, and spread of any changes in PZQ efficacy, 
like resistance; this is particularly because schistosomes have 
sufficient genetic variability to evolve  10–  12   and coevolve  13–  15   and 
artificial selection for PZQ resistance has been shown within 
the laboratory in as few as six generations.  16  
  At present, it is possible to test for PZQ resistance using 
investigations into the dose of PZQ required to kill 50% of 
adult worms   in vivo   (ED  50    )  or   in vitro   PZQ assays on adult 
worms derived from passage through laboratory rodents,  17,  18  
with similar   in vitro   assays also used to test the comparative 
effectiveness of other drugs.  19,  20   These assays, however, present 
strong ethical, logistical, and biological disadvantages, requiring 
high laboratory animal usage and several months for passage, 
with the significant risk of genetic bottlenecks, thereby con-
founding results obtained from such methodologies.  21   Because 
of the location of schistosomes within the mesenteric arteries 
of their mammalian hosts, direct analysis of adult worms from 
human infections is not possible, and although novel tech-
niques for molecular assessment on larval stages have been 
shown,  21   there are, at present, no molecular markers for PZQ 
resistance. Low budget, rapid methods for monitoring para-
site phenotypes are, therefore, crucial, and they could provide 
logistically important information concerning the potential 
PZQ resistance status of natural parasite populations and help 
answer some of the questions posed about drug resistance in 
human infections.  22   The methods presented here, therefore, 
focus on isolates directly from the field to accurately represent 
the parasite populations using low-cost, rapid techniques. 
  Previous work on adult worms, miracidia (larvae hatched 
from eggs excreted by infected mammalian definitive hosts), 
cercariae (larvae released from infective molluscan intermedi-
ate hosts), and eggs has shown that changes in morphology of 
  S. mansoni  , when exposed to   in vitro   PZQ, could reflect   in vivo  
susceptibility,  23   with the larval stages highlighted as more sen-
sitive than adult worms.  23,  24   Indeed, miracidia (and cercariae) 
provide an ideal opportunity to monitor putative changes after 
chemotherapeutic treatment, enabling comparisons between 
parasite populations without possible biases of clearance 
trends, infection intensities, human host immune status, and/or 
PZQ pharmacokinetics. Miracidial shape changes after   in vitro  
PZQ exposure were termed tadpole and dumbbell by Liang 
and others,  24   with greater percentages of change observed in 
PZQ-susceptible than PZQ-resistant isolates.  24   Such tests also 
showed that a higher proportion of miracidia from suscepti-
ble isolates was inactive after 5 minutes of PZQ stress than 
from resistant isolates.  24    In vitro   tests of   S. japonicum   cercariae, 
miracidia, and eggs have indicated that they are more sensitive 
to PZQ than   S. mansoni  , potentially explaining the lack of evi-
dence for resistance in   S. japonicum   from China and highlight-
ing the need to monitor   S. mansoni   populations more closely.  25  
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  Many researchers have pinpointed the need to monitor 
schistosomes in the field as MDA continues, with techniques 
to investigate the mode of action of PZQ as well as to moni-
tor PZQ susceptibility in human infections being a necessity 
for the continued success of such programs.  26   The  laboratory 
aspect of the current study, therefore, expands on work by 
Liang and others  24   by characterizing here the impact of   in vitro  
PZQ on resistant, susceptible, and coinfected   S. mansoni   lines 
under   in vivo   PZQ selection using video capture analysis for 
detailed observations of miracidia behavior and morphology 
over time. The morphological aspects of these original tests on 
  S. mansoni   have, to date, only been evaluated in the field in 
China on   S. japonicum   from infected water buffalo and goats.  27  
The objective of our study was, therefore, to assess, for the first 
time to the authors’ knowledge, the feasibility of use of this 
rapid, inexpensive diagnostic test using   in vitro   PZQ directly 
on   S. mansoni   miracidia from endemic human infections to 
detect PZQ susceptibility under mass chemotherapeutic pres-
sure in a real field environment. Our measures were uniquely 
quantified using highly detailed longitudinal infection inten-
sity, clearance, and reinfection data, including repeated sam-
pling from the same children over time. 
  It was predicted that, when exposed to   in vitro   PZQ, resis-
tant miracidia from the laboratory would show lower propor-
tions of immobility and shape change than the coinfected and 
susceptible lines, supporting the work of Liang and others  24  
When PZQ treatment was administered   in vivo  , these pro-
portions of inactive and dumbbell-shaped miracidia were pre-
dicted to be reduced. It was predicted that children whose 
infections were cleared by a subsequent PZQ treatment would 
show greater miracidial inactivity and shape change than indi-
viduals whose infections were not completely cleared by a 
standard PZQ treatment. 
   MATERIALS AND  METHODS 
  Laboratory.     Parasite  and  host  lines.    Three   S. mansoni   lines, 
PZQ-resistant (R), PZQ-susceptible (S), and coinfection 
(RS), were used. The R line (EE2) is from an   S. mansoni  
isolate established in 1996 from eggs excreted by an inhabitant 
of the Nile region in Egypt before three non-curative PZQ 
treatments of 40, 40, and 60 mg/kg, respectively.  28   The 
resultant parasite line has an ED  50      > 100 mg/kg PZQ and was 
tested at three laboratories in Rome, Bangor, and Egypt.  17  
The S line (MOC) is from an   S. mansoni   isolate established 
in 1996 from eggs excreted by an inhabitant of the Nile 
region in Egypt before receiving a single curative 40 mg/kg 
PZQ treatment.  28   The resultant parasite line has an ED  50  
< 100 mg/kg PZQ.  17   Laboratory lines of   Biomphalaria glabrata  
and   B. alexandrina   were used to passage the R and S lines 
before the investigation. 
   Experimental  design.     Two groups of four female TO Harlan       
adult mice (Harlan Olac UK Ltd., UK) were exposed to 220 
cercariae of each of one of the three   S. mansoni   lines, R, S, or 
RS (110 cercariae of each R and S), through paddling in 100 mL 
of infected water for 30 minutes, giving a total of six groups of 
four mice. Six weeks post-exposure, all mice were weighed and 
ear-marked; then, one group of each parasite line received, by 
oral gavage, a subcurative dose of 50 mg/kg PZQ, and the other 
group received a water (control) dose. Mice were euthanized 
49–56 days post-parasite exposure to achieve maximum parasite 
return before onset of schistosome-induced morbidity. 
  Miracidia were hatched from eggs obtained from the livers 
and spleens of individual mice, which were macerated through 
a sieve in 250 mL of 0.85% saline. The suspension was left for 
10 minutes of sedimentation; then, 240 mL of supernatant 
were removed, fresh saline was added, and sedimentation and 
supernatant removal were repeated. The remaining 10 mL of 
sediment were washed out with 70 mL of spring water and 
illuminated for 1 hour. Miracidia were pooled within groups, 
and from each group, nine sets of six miracidia were placed on 
a Petri dish in 0.1 mL droplets of bottled spring water. Video 
recordings were taken with an Olympus SZ410 (GX Optical, 
Suffolk, UK) triocular dissecting microscope attached to a 
JVC IC-1280E color video camera for 7 minutes. After 2 min-
utes of recording, 0.5 μL of water or PZQ were added, result-
ing in 0, 1 × 10  −6  , or 2 × 10  −6   M PZQ. Three replicates of six new 
miracidia were recorded per experimental group. The behavior 
and shape of five miracidia per droplet were recorded contin-
uously for 7 minutes in 2-second intervals using an electronic 
pacer (Oregon Scientific, UK Ltd., Maidenhead, Berkshire, 
UK). Viewing order was randomized to prevent observational 
bias. Miracidial shape was recorded as normal, tadpole, or 
dumbbell, and the time of any changes was noted. 
   Statistical analysis.   Statistical analyses were performed using 
SPSS (SPSS, Inc., Chicago, IL). The data for time from PZQ 
addition until miracidial inactivity and the proportion that 
became inactive were normally distributed, whereas the time 
for miracidia to become dumbbell was log-transformed to a 
normal distribution. The impact of parasite genotype and   in 
vivo   and   in vitro   PZQ on the time taken to become dumbbell 
and/or inactive was analyzed using a general linear model. 
The categorical data of the numbers that became inactive or 
dumbbell was analyzed using the Kruskal-Wallis test. 
    Field.     Individuals were recruited from three primary schools 
in Mayuge, Uganda: Bugoto Lake View (LV), Bwondha, 
and Musubi Church of God (CoG). Cohorts consisted of 
approximately 18 randomly selected children per 6-, 7-, 8-, and 
11-year-old age group, with an equal sex ratio within each group. 
All children aged 7 to 11 years from Bugoto LV and Bwondha 
had previously received PZQ treatment in July 2003 and July 
2004 as part of the SCI annual control program, whereas all 
children from Musubi CoG and the new 6-year-old recruits 
from Bugoto LV and Bwondha had received PZQ treatment in 
July 2004. In July 2004, infection intensity data using 3 successive 
days of double Kato Katz (KK) smears  29   were collected pre-
treatment, 1 week post-PZQ treatment, and 4 weeks post-PZQ 
treatment. All children were treated after the pre-treatment 
sampling point      , and all children with positive KK results were 
retreated at 1 week and 4 weeks post-treatment. 
  This study was carried out in February 2005, 6 months after 
the children’s most recent exposure to PZQ. Infection inten-
sity was measured as noted above and miracidia hatched from 
infected individuals’ stools (pre-retreatment). All children 
surveyed were treated with 40 mg/kg PZQ. One week later, 
the schools were revisited, and intensity measures and hatch-
ing was repeated (post-retreatment). After this 1-week follow-
up, only children with KK-positive smears were retreated with 
40 mg/kg PZQ. Schools were revisited 6 months later (August 
2005). Infection intensity and prevalences were measured to 
investigate clearance and reinfection trends, and all children 
surveyed were retreated with 40 mg/kg PZQ. 
  At the pre- and post-retreatment time points, schistosome 
eggs from individual stool samples were hatched. Samples 1342 LAMBERTON AND OTHERS
were passed though a 425-μm sieve with ~1 L of bottled spring 
water; the suspension was then filtered through a pitchford 
funnel, consisting of an inner mesh of 80 μm to collect larger 
debris but allow parasite eggs through it and an outer mesh 
of 40 μm to collect the eggs. The sediment was rinsed using 
1–2 L spring water. The eggs were released into a Petri dish 
and placed in indirect sunlight for up to 6 hours. 
    PZQ behavior response profiling.     Eight miracidia from each 
stool sample were placed into each of three wells with 1 mL 
spring water. Miracidia were observed continuously for 10 
seconds every 30 seconds over 7 minutes, with 5 μL water or 
PZQ solution added after 2 minutes to make concentrations 
of 0, 1 × 10  −6  , or 2 × 10  −6   M PZQ. Individual miracidium shapes 
were recorded as normal, tadpole, or dumbbell at each point 
of activity across the well (1 cm diameter) and at the end 
of 7 minutes. Each experiment was repeated three times per 
child for each   in vitro   PZQ concentration. 
   Statistical analyses.   The percentages of inactive miracidia and 
shape change after 5 minutes of exposure were analyzed using 
paired and unpaired   t   tests for comparisons between pre- and 
post-retreatment, clearance trends,   S. mansoni   prevalence at 
4 weeks,   S. mansoni   prevalence at 6 months, recruitment year, 
and   in vitro   PZQ treatments. A one-way analysis of variance 
(ANOVA) was used to analyze the effect of the number of 
previous PZQ treatments. Data that showed a slight positive 
skew were square root-transformed. Where data could not 
be transformed to an approximately normal distribution, 
Kruskal–Wallis or Mann–Whitney tests were used. 
    Ethical  clearance.     The animal work was performed under 
Home Office Project License PPL 30/2032, and all procedures 
were classed as mild. Ethical approval for the parasite material 
and infection intensity data obtained from the field was obtained 
from the Uganda National Council of Science and Technology 
and the Imperial College Research Ethics Committee 
(ICREC), Imperial College, London, United Kingdom in 
combination with the ongoing SCI activities. Written consent 
for the schoolchildren to participate in longitudinal monitoring 
of the national control program for schistosomiasis and soil 
transmitted helminths       was given by head teachers because of 
the fact that, in African schools, written consent of the child’s 
guardian is very difficult to obtain (owing to the associated 
impoverished conditions and often low literacy). The parents/
guardians verbal consent was recorded at school committees 
comprising of parents, teachers, and community leaders after 
they received satisfactory information about the study. Each 
individual child also gave verbal consent before recruitment. 
    RESULTS 
  Laboratory.     In the control 0 M PZQ groups (not exposed to 
  in vitro   PZQ but from treated and untreated mice), all miracidia 
remained active and normally shaped over the duration of the 
study. In the   in vitro   PZQ-treated groups, miracidia from the 
untreated mice showed greater immobility in the higher   in vitro  
PZQ concentration than miracidia from treated mice (Kruskal-
Wallis test statistic [H]       = 32.425, degrees of freedom [df] = 2, 
  P   < 0.001), with the S miracidia showing higher immobility than 
both the RS and R (H = 26.418, df = 2,   P   < 0.001) (  Figure 1A  ). 
Miracidia from PZQ-treated mice showed higher immobility 
at the higher   in vitro   PZQ concentration (H = 32.685, df = 2, 
  Figure   1.     Effect  of   in vitro   praziquantel (PZQ) on miracidia from treated and untreated mice. Proportion (±SE) of inactive miracidia PZQ-
resistant (R), PZQ-susceptible (S), and co-infected (RS) after 5 minutes exposure to two   in vitro   PZQ concentrations of (  A  ) miracidia hatched from 
untreated mice and (  B  ) miracidia hatched from mice treated with 50 mg/kg PZQ.       1343 IN VITRO PRAZIQUANTEL TEST DETECTS REDUCED EFFICACY IN VIVO
  P   < 0.001), but the proportions of immobile miracidia were not 
affected by parasite genotype, with the proportion of inactive S 
miracidia similar to RS and R (  Figure 1B  ). The time taken for 
miracidia to become inactive after exposure to   in vitro   PZQ 
was also shortest for S (F  2,26   = 3.358,   P   = 0.050; S = 46.17 ± 
17.01 seconds, RS = 208.86 ± 29.63 seconds, R = 145.20 ± 34.61 
seconds). 
    Alteration to dumbbell shape in all treatment groups 
occurred faster in 2 × 10  −6   M (28.16 ± 2.73 seconds) than 1 × 
10  −6   M PZQ (37.01 ± 3.36 seconds; F  1,160   = 8.039,   P   = 0.005), and 
miracidia hatched from treated mice took longer to become 
dumbbell than those from untreated mice (34.56 ± 2.95 seconds 
and 30.72 ± 3.24 seconds, respectively; F  1,160   = 4.574,   P   = 0.034). 
   Field.     In the control 0 M PZQ groups, all miracidia remained 
active, and 99.7% were normally shaped throughout the 
duration of the study. In contrast, shape change and immobility 
was observed in all   in vitro   PZQ groups. Significantly more 
miracidia became dumbbell-shaped at the stronger  in vitro  PZQ 
concentration (F  2,30   = 24.237,   P   < 0.001), and more miracidia 
were inactive after 5 minutes at the higher concentration both 
pre- (F  2,21   = 21.999,   P   < 0.001) and post-treatment (F  2,18   = 7.103, 
  P   = 0.005) than at the lower 10  −6  -M PZQ concentration. 
    Impact of human chemotherapy.     The proportion of inactive 
(paired   t   test,   t   = 2.709, df = 7,   P   = 0.030) (  Figure 2A  ) and 
dumbbell (paired:   t   = 2.538, df = 7,   P   = 0.039; unpaired:   t   = 
2.208, df = 12,  P  = 0.047) ( Figure 2B  and C) miracidia 5 minutes 
after   in vitro   PZQ exposure was significantly lower 1 week 
post-retreatment than in those hatched pre-retreatment. In 
addition, however, the number of normally shaped miracidia 
was higher pre-retreatment than post-retreatment in both PZQ 
concentrations, although only nearly statistically significant in 
the paired samples (paired:  t  = 1.915, df = 7,  P  = 0.097; unpaired: 
  t   = 1.367, df = 12,   P   = 0.197). Of miracidia hatched from eight 
children pre-retreatment, four children had lower infection 
intensities 1 week post-retreatment, whereas four had higher 
epgs. Of those with lower infection intensities (lower epgs), 
there was a non-significant trend for a greater proportion of 
dumbbell miracidia pre-treatment than in those that were 
not lowered by MDA, whereas the number of normal-shaped 
miracidia remained unaffected (  Figure 3A and B  ). Miracidia 
hatched from individuals who were KK-negative at 4 weeks 
(5 months before this study) and therefore, assumed-to-be-
new PZQ-naive infections showed higher inactivity than that 
from individuals who had still been KK-positive at 4 weeks 
(even after two or more PZQ treatments). 
      S. mansoni  prevalence at follow-up.   Six of the children sampled 
here in February 2005 were successfully resampled 6 months 
later in August 2005, with 3 days of double KKs repeated. 
Three children were KK-negative for   S. mansoni   (therefore, 
assumed to be cleared by the one additional PZQ treatment in 
February), and three were KK-positive. There was a significantly 
higher proportion of dumbbell (  t   = 5.588, df = 10,   P   < 0.001) 
and immobile miracidia (  t   = 2.56, df = 10,   P   = 0.027) from the 
individuals who were subsequently KK-negative 6 months later 
compared with those that were KK-positive (  Figure 4  ). 
    Previous  PZQ  treatments.     There was a non-significant 
effect of the total number of PZQ treatments received by the 
children on the proportion of miracidial inactivity and shape 
change (ANOVA: F = 2.768,   P   = 0.063); however, this was not 
linearly associated with the number of treatments as predicted 
(regression: F = 0.213,   P   = 0.648). Instead, miracidia from 
individuals that had received one or three PZQ treatments 
(of which seven of eight of the tests were carried out 
pre-retreatment) had a significantly higher proportion of 
immobile (  t   = 3.417, df = 28,   P   = 0.002) and dumbbell miracidia 
(  t   = 2.677, df = 28,   P   = 0.012) than those from individuals that 
had received two or four PZQ treatments (where 5/7 were 
tested 1 week post-treatment). 
     DISCUSSION 
  In vitro   PZQ has been shown to significantly affect the 
shape and mobility of   S. mansoni   miracidia, with responses 
depending on the parasites’ genotype and   in vivo   PZQ expo-
sure. Furthermore, this bioassay has been shown here to be 
sufficiently sensitive to serve as a predictor of clearance trends 
in the field, strongly endorsing the possible use of this rapid 
and inexpensive diagnostic test in natural foci. 
  Human infections that seemed to be more susceptible to 
PZQ (with lower intensities 1 week post-retreatment) had 
more dumbbell and inactive miracidia pre-retreatment than 
those that were less susceptible to PZQ (identified as being 
uncleared by an additional PZQ administration). In addition, 
the miracidia hatched 1 week post-retreatment also had less 
shape change and inactivity than those hatched before retreat-
ment. This strongly supported our laboratory findings; more 
inactive miracidia were observed as parasite susceptibility 
increased from R to RS to S as well as miracidia from PZQ-
treated mice took longer to change shape than those from 
untreated mice. Time to shape change may, therefore, also be an 
important indicator of reduced susceptibility to PZQ as well as 
the proportions that change shape. However, not R, as may be 
predicted, but RS miracidia took the longest to become immo-
bile, although this could be explained by an overall increase in 
fitness in this coinfected line by the unavoidable outbreeding 
between lines maintained within the laboratory for many gen-
erations. Variations found in the RS group could also depend 
on the inheritance of PZQ resistance  30   and potentially, the 
higher susceptibility of male than female schistosomes com-
monly reported in adult worms;  24,  31   this was also more recently 
shown in the cercarial larval stage of   S. mansoni , 32   and, if also 
common in miracidia, these results may, therefore, also depend 
on the ratio of male to female eggs and subsequent miracidia. 
  Further evidence for this test’s sensitivity on miracidia from 
human infections was illustrated by its ability to detect dif-
ferences between new infections in children who were nega-
tive 5 months previously with parasite populations assumed to 
be PZQ-naïve and infections in those children that may have 
remained infected even after two or more PZQ treatments. 
In addition, miracidia hatched from individuals that were 
KK-negative 6 months later (whose infections have, therefore, 
been cleared by a single subsequent treatment and classified as 
PZQ-susceptible) showed significantly higher levels of inactiv-
ity than those that were potentially PZQ-resistant, shown by 
positive KK smears 6 months after additional PZQ treatments. 
It may, however, be argued that these infections could have 
been caused by reexposure as well as some non-clearance, an 
explanation supported by molecular analysis of miracidia from 
these populations (Lamberton PHL and others, unpublished 
data). Although untreated groups were not investigated for eth-
ical considerations, it can be argued that observed differences 
are primarily caused by PZQ exposure, particularly because of 
the strong significance of the paired tests where miracidia were 
hatched from the same individuals at two different time points. 1344 LAMBERTON AND OTHERS
  Although efforts were made to use samples from children 
with a wide range of infection intensities, variations in hatch-
ing success may also explain differences in results between 
the two time points. However, the clear significant differences 
between samples hatched at the same time point from similar 
infection intensities that then differed greatly in their clear-
ance after another PZQ treatment indicate that the observed 
differences are caused by actual variations in PZQ sensitivity 
in the parasites. 
  The effect of recent PZQ treatment seemed to be more 
important than the total number of treatments that an indi-
vidual had received. One potential explanation may be that 
parasites with a higher survival to recent PZQ treatment could 
be assumed to be more resistant than those that have a lower 
survival, irrelevant of the number of previous PZQ exposures, 
potentially explained by relatively high levels of reinfection. 
An alternative explanation could be the effect of PZQ on 
  S. mansoni   eggs still within the host  33   rather than on the adult 
  Figure   2.        Differences between parasite populations pre- and post-praziquantel (PZQ) treatment. (  A  ) Percentage of inactive miracidia per 
treatment group (±SE) after 5 minutes exposure to   in vitro   PZQ treatment of miracidia hatched at two different time points. One group hatched 
pre-retreatment with PZQ (pre), and the other group hatched from individuals 1 week after retreatment with 40 mg/kg PZQ (post). Proportion of 
miracidia that was normal-, tadpole-, or dumbbell-shaped after 5 minutes exposure to   in vitro   PZQ treatment (  B  ) pre-retreatment and (  C  ) 1 week 
post-retreatment.    1345 IN VITRO PRAZIQUANTEL TEST DETECTS REDUCED EFFICACY IN VIVO
worms. Mature eggs have been observed to be more suscep-
tible to PZQ than immature eggs.  34   Knowledge of the average 
time that eggs take to mature and be excreted from the body 
and the ability of adult worms to produce eggs under PZQ 
stress would help to elucidate possible causes for these dif-
ferences in miracidial responses. If eggs are excreted within 
1 week of production, then differences in the miracidia pre- and 
1 week post-PZQ would be caused by variation in adult worm 
survival and their subsequent egg production. If, however, 
excretion takes over 1 week, then the differences observed 
  Figure   3.     Variations  in  clearance  rates  represented  by   in vitro   tests. Proportion of miracidia hatched pre-retreatment, which were normal-, 
tadpole-, or dumbbell-shaped after 5 minutes exposure to the   in vitro   treatment, from individuals whose infection intensities were (  A  ) lower 1 week 
post-retreatment or (  B  ) higher 1 week post-retreatment.       
  Figure   4.        Variations in miracidia activity correlated with long-term parasite clearance. Percentage of inactive miracidia (±SE), hatched from 
individuals 1 week post-retreatment with 40 mg/kg praziquantel (PZQ), after 5 minutes exposure to   in vitro   PZQ treatment that was either Kato 
Katz-negative 6 months later, meaning that the infection had been cleared by a single subsequent PZQ treatment, or Kato Katz-positive 6 months 
later and therefore, with potentially reduced susceptibility to PZQ.       1346 LAMBERTON AND OTHERS
here could be because of   in vivo   PZQ exposure directly on the 
eggs rather than the adults. Studies on the effect of the immune 
system as well as PZQ directly on the eggs may help elucidate 
this further and expand on the current research on adult worm 
teguments and the mode of action of PZQ.  35   Detailed   in vitro  
research can be hugely helpful in not only monitoring PZQ 
resistance but also understanding the drug’s mechanisms. 
  The results from this study show that the proportion of 
dumbbell-shaped miracidia and inactivity are strong indica-
tors of reduced sensitivity to PZQ within human infections. 
The number of normal-shaped miracidia, however, actually 
seemed to be higher in samples hatched pre-retreatment than 
1 week later. Miracidia that remain normal under   in vitro   PZQ 
pressure are considered to be resistant. Because this study was 
carried out 6 months after an MDA intervention, the presence 
of more normal-shaped miracidia pre-retreatment could be 
explained by parasites that are slightly resistant to PZQ and 
were uncleared by the last PZQ dose 6 months ago but were 
now cleared by an additional PZQ treatment, especially as the 
proportion of normal miracidia pre-PZQ were only weakly 
significantly higher in the paired samples. Such results may 
also, however, be partly caused by underlying natural para-
site genetic heterogeneity,  36   supporting the finding that no sig-
nificant difference was found in the larger group of unpaired 
samples. 
  For modeling evolutionary predictions on the spread of cer-
tain genotypes, such as PZQ resistance, throughout a popu-
lation, key factors involve knowing how many resistant or 
tolerant parasites there are in an untreated population. If one 
population, for example, is more susceptible than another 
population, then the more susceptible population will have 
fewer genes for resistance in an unselected group and there-
fore, be less likely to develop resistance after chemotherapy. 
It is, therefore, of vital importance that more research be car-
ried out in true PZQ-naïve populations, particularly involving 
methods such as those discussed here, to analyze the propor-
tion and later, any spread of reduced sensitivity to PZQ. In 
addition, investigations under contrasting MDA conditions 
within and between different countries for   S. mansoni   as well 
as studies on   Schistosoma haematobium  , which seems to be 
more susceptible to PZQ than   S. mansoni , 37   would provide 
vital information on the status and understanding of parasite 
PZQ susceptibility. These would also help to clarify standard 
operating procedures needed for such a test so that it could be 
easily and accurately incorporated within an MDA program. 
   CONCLUSIONS 
  The impact of   in vitro   PZQ on miracidial shape and mobil-
ity was shown to closely reflect   in vivo   susceptibility in labora-
tory untreated mice; however, even S parasites that survived 
  in vivo   PZQ were less susceptible   in vitro  . PZQ miracidial test 
results were uniquely shown to be associated with clearance 
trends in individual human infections, indicating a highly fea-
sible use of   in vitro   PZQ as a diagnostic tool to detect poten-
tial resistant genotypes and provide important insights into 
parasite population structure within this and similar schisto-
some-endemic regions. Although clearance rates remain high 
in these MDA areas, this study has shown, for the first time, 
that miracidia populations hatched after PZQ treatment are 
phenotypically different from those hatched before and that 
those hatched before subsequent clearance are different from 
those that remained uncleared. Our results thereby illustrate 
the exciting possible uses of this bioassay as well as highlight 
the need for continued monitoring of the parasite populations, 
potentially through such assays, as treatments progress. Such 
a phenotypic measure for testing potential resistance may be 
highly important now with the increase in and expansion of 
MDA, particularly given the current lack of genetic markers 
available. 
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